62 patents currently held
124 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Oct 2027. from the record
Of the 124 now held by other companies, 70 name Takeda Pharmaceutical Company Limited as their current owner, and 54 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
32
Ending by 2030
Oct 2027
Next term end
41
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2039 · High confidence
Also notable
Ends Nov 2027 · High confidence
Also notable
Ends May 2032 · High confidence
Autoinjector
US D1,010,817
Cited by 23 later US patents, top 5% of design patents granted in 2024 in our data. Protection runs to 2039.
Aurora Kinase Inhibitors for Inhibiting Mitotic Progression
US 9,988,384
Cited by 23 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2027.
Heterocyclic Compounds and Uses Thereof
US 9,085,560
Cited by 33 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Formerly held, still cited
Notable
Ends Oct 2037 · High confidence
Cited by 13 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
conveyed to Takeda Pharmaceutical Company Limited - now held by Sumitomo Pharma Co., Ltd.
Also notable
Ends Aug 2027 · High confidence
Cited by 62 later US patents, top 25% of utility patents granted in 2008 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by Takeda Pharmaceutical Company Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 23, 2026The maintenance fee for Heteroaryls and Uses Thereof (US 9,062,038) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
- 2 fees due Jan 21 to 28, 2027 · next Jan 21
- 2 fees due Feb 4 to 27, 2027 · next Feb 4
- 2 fees due Mar 8 to 22, 2027 · next Mar 8
- 1 fee due Apr 17, 2027The maintenance fee for Solid Pharmaceutical Compositions and Processes for Their Production (US 11,786,470) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due May 3, 2027The maintenance fee for Solid Pharmaceutical Compositions and Processes for Their Production (US 9,173,846) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Systems and Methods for Filling Containers (US 11,926,445) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Aurora Kinase Inhibitors for Inhibiting Mitotic Progression (US 11,958,855) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
- 3 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 41 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compounds and Methods for Inhibiting Mitotic Progression | 11 in force | to Jul 2036 |
| Autoinjector | 3 in force | to Aug 2039 |
| Systems and Methods for Filling Containers | 3 in force | to Apr 2039 |
| Heterocyclic Compounds and Uses Thereof | 2 in force | to May 2032 |
| Crystalline Forms of Sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate | 2 in force | to Sep 2031 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D691,880 | Tray for Increasing Compliance in the Administration of a Medicament by More Than One Route In force · Medium confidence | In force | Medium confidence | |
| US 9,221,758 | Methods of Synthesizing Pharmaceutical Salts of a Factor Xa Inhibitor In force · High confidence | In force | High confidence | |
| US D692,749 | Tray for Increasing Compliance in the Administration of a Medicament by More Than One Route In force · Medium confidence | In force | Medium confidence | |
| US 9,765,076 | Aurora Kinase Inhibitors for Inhibiting Mitotic Progression In force · High confidence | In force | High confidence | |
| US 9,988,384 | Aurora Kinase Inhibitors for Inhibiting Mitotic Progression In force · High confidence | In force | High confidence | |
| US 10,836,766 | Aurora Kinase Inhibitors for Inhibiting Mitotic Progression In force · High confidence | In force | High confidence | |
| US D695,122 | Carton In force · Medium confidence | In force | Medium confidence | |
| US D695,123 | Carton In force · Medium confidence | In force | Medium confidence | |
| US D695,124 | Carton In force · Medium confidence | In force | Medium confidence | |
| US D695,125 | Carton In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 62: 124 patents in force now held by others · 278 patents ended · 43 applications pending · 655 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.